appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
BadThe stock is in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Panacea Biotec Ltd
PANACEABIO
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
BadThe stock is in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations.
PeersCompare with peers
Biocon Ltd
Hester Biosciences Ltd
Zenotech Laboratories Ltd
Transgene Biotek Ltd
Vivo Bio Tech Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Updates
Press Release
Panacea Biotec Limited has informed the Exchange regarding a press release dated September 12, 2024, titled "DFC Commits US$20 Million Long-Term Loan to Panacea Biotec Limited towards Capacity-Expansion Project for Hexavalent Vaccine EasySix?". | Download
Panacea Biotec Limited has informed the Exchange regarding a press release dated September 12, 2024, titled "DFC Commits US$20 Million Long-Term Loan to Panacea Biotec Limited towards Capacity-Expansion Project for Hexavalent Vaccine EasySix?". | Download
Cash Dividend
Final • Div/Share: ₹ 0.75
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant